Use of reslizumab to treat moderate to severe eosinophilic asthma

Patent metadata

Field	Value
Publication number	US-9815894-B2
Application number	US-201514838503-A
Country	US
Kind code	B2
Filing date	Aug 28, 2015
Priority date	Sep 8, 2014
Publication date	Nov 14, 2017
Grant date	Nov 14, 2017

Abstract

Disclosed herein are methods of treating moderate to severe eosinophilic asthma in a patient comprising administering a therapeutically effective dose of reslizumab to a patient whose symptoms are inadequately controlled with a current asthma therapeutic and wherein the patient's blood eosinophil levels are equal to or greater than 400/μL.

First claim

What is claimed:

1. A method of treating moderate to severe eosinophilic asthma in a patient comprising:
administering a therapeutically effective dose of reslizumab to the patient, wherein
prior to the administering, the patient's symptoms are inadequately controlled with a current asthma therapeutic and the patient's blood eosinophil levels are equal to or greater than 400/μl; and
following the administering, the patient exhibits a significantly improved FEV 1 treatment effect and wherein the patient's use of systemic corticosteroids is reduced by about 50% as compared to a patient not receiving reslizumab.

2. The method of claim 1 , wherein the patient's blood eosinophil levels are equal to or greater than 500/μl, 600/μl, 700/μl, or 800/μl.

3. The method of claim 1 , wherein the therapeutically effective dose of reslizumab is about 0.3 mg/kg to about 3 mg/kg.

4. The method of claim 1 , wherein the therapeutically effective dose of reslizumab is administered intravenously or subcutaneously.

5. The method of claim 1 , wherein the therapeutically effective dose of reslizumab is administered once about every 4 weeks.

6. The method of claim 1 , wherein the current asthma therapeutic comprises an inhaled corticosteroid.

7. The method of claim 6 , wherein the current asthma therapeutic comprises a medium dose inhaled corticosteroid.

8. The method of claim 7 , wherein the inhaled corticosteroid is at least equivalent to about 440 μg fluticasone.

9. The method of claim 6 , wherein the inhaled corticosteroid comprises a high dose of inhaled corticosteroid.

10. The method of claim 6 , wherein the current asthma therapeutic further comprises a long acting beta 2 adrenoceptor agonist.

11. The method of claim 1 , wherein administration of the therapeutically effective dose of reslizumab also leads to an improvement in lung function, as assessed by forced vital capacity, forced expiratory flow rate, or any combination thereof.

12. The method of claim 11 , wherein the improvement in lung function is equal to or greater than about 5% as compared to a patient not receiving reslizumab.

13. The method of claim 1 , wherein administration of the therapeutically effective dose of reslizumab leads to a reduction of clinical asthma exacerbations, reduction of use of systemic corticosteroids, improved asthma control questionnaire score, improved asthma quality of life questionnaire score, or any combination thereof.

14. The method of claim 13 , wherein the clinical asthma exacerbations are reduced by about 50% as compared to a patient not receiving reslizumab.

Assignees

• O'Brien Christopher
• Zangrilli James
• Shah Tushar
• Cephalon Inc

Inventors

• O'Brien Christopher
• Zangrilli James
• Shah Tushar

Classifications

• C07K2317/24

  containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered · CPC title

• A61K2039/507

  Comprising a combination of two or more separate antibodies · CPC title

• A61P11/06

  Antiasthmatics · CPC title

• A61K2039/505

  comprising antibodies · CPC title

• A61K2039/545

  characterised by the dose, timing or administration schedule · CPC title